An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia
Michael Dussiot,Thiago T Maciel,Aurélie Fricot,Céline Chartier,Olivier Negre,Joel Veiga,Damien Grapton,Etienne Paubelle,Emmanuel Payen,Yves Beuzard,Philippe Leboulch,Jean-Antoine Ribeil,Jean-Benoit Arlet,Francine Coté,Geneviève Courtois,Yelena Z Ginzburg,Thomas O Daniel,Rajesh Chopra,Victoria Sung,Olivier Hermine,Ivan C Moura
DOI: https://doi.org/10.1038/nm.3468
Abstract:The pathophysiology of ineffective erythropoiesis in β-thalassemia is poorly understood. We report that RAP-011, an activin receptor IIA (ActRIIA) ligand trap, improved ineffective erythropoiesis, corrected anemia and limited iron overload in a mouse model of β-thalassemia intermedia. Expression of growth differentiation factor 11 (GDF11), an ActRIIA ligand, was increased in splenic erythroblasts from thalassemic mice and in erythroblasts and sera from subjects with β-thalassemia. Inactivation of GDF11 decreased oxidative stress and the amount of α-globin membrane precipitates, resulting in increased terminal erythroid differentiation. Abnormal GDF11 expression was dependent on reactive oxygen species, suggesting the existence of an autocrine amplification loop in β-thalassemia. GDF11 inactivation also corrected the abnormal ratio of immature/mature erythroblasts by inducing apoptosis of immature erythroblasts through the Fas-Fas ligand pathway. Taken together, these observations suggest that ActRIIA ligand traps may have therapeutic relevance in β-thalassemia by suppressing the deleterious effects of GDF11, a cytokine which blocks terminal erythroid maturation through an autocrine amplification loop involving oxidative stress and α-globin precipitation.